Abstract
Cholangiocarcinoma is an uncommon tumour that may occur anywhere along the intrahepatic or extrahepatic biliary tree. In the United States approximately 4000–5000 cholangiocarcinomas are diagnosed per year. The hepatic duct bifurcation is the most frequently involved site, and approximately 60–80% of cholangiocarcinomas are found in this perihilar region [ 1 x [1] Nakeeb, A., Pitt, H.A., Coleman, J., Hraban, R.H., Abrams, R.A., and Cameron, J.L. Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996; 224: 463–475 Crossref | PubMed | Scopus (783) | Google Scholar See all References 1 ]. The role of radiation therapy, chemotherapy and chemoradiation as adjuvants to surgical resection in patients with perihilar cholangiocarcinoma remains controversial. Aggressive surgical resection obtaining a negative microscopic margin offers the only chance for long‐term survival. Unfortunately, many patients will only be candidates for palliative bypass or operative or non‐operative intubation aimed to provide biliary drainage and prevent cholangitis and hepatic failure. Radiation therapy, chemotherapy and/or chemoradiation also can be used in these patients with non‐resectable disease in an attempt to palliate symptoms and extend survival.

This publication has 12 references indexed in Scilit: